BlueAllele Corp. stole Intellia Therapeutics Inc.’s pioneering gene-editing technology for inserting healthy DNA into genes to enhance genetic-disease treatments and falsely claimed inventorship of patents central to treating genetic disorders, Intellia said in a court filing.
BlueAllele used Intellia’s patented experimental designs, misrepresented data to the US Patent and Trademark Office, and leveraged stolen technology to secure investor funding, Intellia argued in its answer and counterclaims filed Monday in the US District Court for the District of Delaware.
“Because of BlueAllele’s wrongful business conduct, Intellia has lost the full value of rights to patents based on bidirectional technology it invented,” ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.